Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Summaries for patients: Oral drug treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.

[No authors listed]

Ann Intern Med. 2012 Feb 7;156(3):I36. doi: 10.7326/0003-4819-156-3-201202070-00004. No abstract available.

PMID:
22312157
2.

Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.

Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians.

Ann Intern Med. 2012 Feb 7;156(3):218-31. doi: 10.7326/0003-4819-156-3-201202070-00011. Erratum in: Ann Intern Med. 2012 May 15;156(10):756. Ann Intern Med. 2012 Jul 17;157(2):152.

PMID:
22312141
3.

Saxagliptin + metformin. Mostly disadvantages.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):40. No abstract available.

PMID:
23444500
4.

[New class of oral antidiabetic drugs. Effective in combination with metformin].

[No authors listed]

MMW Fortschr Med. 2007 Jan;149(1-2):17. German. No abstract available.

PMID:
17619359
5.

Metformin/Repaglinide (PrandiMet) for type 2 diabetes.

[No authors listed]

Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3. No abstract available.

PMID:
19478691
6.

[Early insulin treatment in type 2 diabetes--yes].

Schumm-Draeger PM.

Dtsch Med Wochenschr. 2013 May;138(18):956. doi: 10.1055/s-0032-1332975. Epub 2013 Apr 23. German. No abstract available.

PMID:
23613375
7.

Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?

[No authors listed]

Ann Intern Med. 2011 Jan 18;154(2):I-40. doi: 10.7326/0003-4819-154-2-201101180-00301. Epub 2010 Dec 6. No abstract available.

PMID:
21135289
8.
9.

Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes.

Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, Lai YL, Jin X, Misir S, Nagendran S, Jones MR.

Endocr Pract. 2010 Jul-Aug;16(4):629-40. doi: 10.4158/EP10130.OR.

PMID:
20634175
10.

Monitoring safety and effectiveness in patients receiving metformin.

Choe HM, Cornish L, Townsend K, Jobe J, Mitrovich S.

Am J Health Syst Pharm. 2004 Aug 1;61(15):1550-1. No abstract available.

PMID:
15372824
12.

Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin.

Flory JH, Small DS, Cassano PA, Brillon DJ, Mushlin AI, Hennessy S.

J Comp Eff Res. 2014 Jan;3(1):29-39. doi: 10.2217/cer.13.87.

13.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
14.

Summaries for patients. Metformin for patients with type 2 diabetes mellitus.

[No authors listed]

Ann Intern Med. 2002 Jul 2;137(1):I50. No abstract available.

PMID:
12093266
15.

Glyburide/metformin HCl clinical overview.

Seymour A.

Manag Care. 2001 Feb;10(2 Suppl):11-6. Review. No abstract available.

16.

[Type 2 diabetic patient with reduced beta-cell function. New substance class: incretin-mimetics].

[No authors listed]

MMW Fortschr Med. 2005 Aug 4;147(31-32):55. German. No abstract available.

PMID:
16128203
17.

Course of glycaemia in poorly controlled type 2 diabetes patients 2.5 years after optimizing oral treatment in general practice.

Berghout LM, Gorter KJ, Rutten GE.

Eur J Gen Pract. 2006;12(2):80-2. No abstract available.

PMID:
16945883
18.

Summaries for patients. Exenatide therapy for type 2 diabetes.

[No authors listed]

Ann Intern Med. 2007 Apr 3;146(7):I18. No abstract available.

PMID:
17404346
19.

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.

Rodríguez A, Reviriego J, Karamanos V, del Cañizo FJ, Vlachogiannis N, Drossinos V; ECLA Study Group.

Cardiovasc Diabetol. 2011 Feb 11;10:18. doi: 10.1186/1475-2840-10-18.

20.

A simple therapeutic combination for type 2 diabetes.

Yki-Järvinen H.

Hosp Pract (1995). 2000 Jul 15;35(7):63-6, 72-4.

PMID:
10916505
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk